oxidopamine has been researched along with Movement Disorders in 43 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was evaluation the effect of Gallic acid on movement disorders and pallidal electrical power in animal model of Parkinson's Disease (PD)." | 3.77 | Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease. ( Farbood, Y; Mansouri, SM; Sameri, MJ; Sarkaki, A, 2011) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| "Pretreatment with genistein, an isoflavone, significantly preserved motor function in rats injected with low-dose 6-OHDA, as evaluated by the stepping and cylinder tests." | 1.35 | Preventive effects of genistein on motor dysfunction following 6-hydroxydopamine injection in ovariectomized rats. ( Kyuhou, S, 2008) |
| "Rats treated with bromocriptine exhibited rotational sensitisation but no AIMs." | 1.34 | The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. ( Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (16.28) | 18.7374 |
| 1990's | 5 (11.63) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kozioł, E | 1 |
| Skalicka-Woźniak, K | 1 |
| Michalak, A | 1 |
| Kaszubska, K | 1 |
| Budzyńska, B | 1 |
| Ma, Y | 1 |
| Zhan, M | 1 |
| OuYang, L | 1 |
| Li, Y | 1 |
| Chen, S | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Luo, C | 1 |
| Lei, W | 1 |
| Didonet, JJ | 1 |
| Cavalcante, JC | 1 |
| Souza, Lde S | 1 |
| Costa, MS | 1 |
| André, E | 1 |
| Soares-Rachetti, Vde P | 1 |
| Guerrini, R | 1 |
| Calo', G | 1 |
| Gavioli, EC | 1 |
| Willard, AM | 1 |
| Bouchard, RS | 1 |
| Gittis, AH | 1 |
| Lee, M | 1 |
| Ryu, YH | 1 |
| Cho, WG | 1 |
| Kang, YW | 1 |
| Lee, SJ | 1 |
| Jeon, TJ | 1 |
| Lyoo, CH | 1 |
| Kim, CH | 1 |
| Kim, DG | 1 |
| Lee, K | 1 |
| Choi, TH | 1 |
| Choi, JY | 1 |
| Czarnecka, A | 1 |
| Konieczny, J | 1 |
| Lenda, T | 1 |
| Lorenc-Koci, E | 1 |
| Esteves, AM | 1 |
| Lopes, C | 1 |
| Frank, MK | 1 |
| Arida, RM | 1 |
| Frussa-Filho, R | 1 |
| Tufik, S | 1 |
| de Mello, MT | 1 |
| Liang, C | 1 |
| Xu, Y | 1 |
| Zheng, D | 1 |
| Sun, X | 1 |
| Xu, Q | 1 |
| Duan, D | 1 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Barnum, CJ | 1 |
| Bishop, C | 1 |
| Kyuhou, S | 1 |
| Krishnamurthi, RV | 1 |
| Mathai, S | 1 |
| Kim, AH | 1 |
| Zhang, R | 1 |
| Guan, J | 1 |
| Kääriäinen, TM | 1 |
| García-Horsman, JA | 1 |
| Piltonen, M | 1 |
| Männistö, PT | 1 |
| Hahn, M | 1 |
| Timmer, M | 1 |
| Nikkhah, G | 2 |
| Young, CK | 1 |
| Koke, SJ | 1 |
| Kiss, ZH | 1 |
| Bland, BH | 1 |
| Brown, AR | 2 |
| Hu, B | 2 |
| Antle, MC | 2 |
| Teskey, GC | 2 |
| Li, XH | 1 |
| Wang, JY | 1 |
| Gao, G | 1 |
| Chang, JY | 1 |
| Woodward, DJ | 1 |
| Luo, F | 1 |
| O'Sullivan, DB | 1 |
| Harrison, PT | 1 |
| Sullivan, AM | 1 |
| Sameri, MJ | 1 |
| Sarkaki, A | 1 |
| Farbood, Y | 1 |
| Mansouri, SM | 1 |
| Fleming, SM | 1 |
| Schallert, T | 2 |
| Ciucci, MR | 1 |
| Delaville, C | 1 |
| Zapata, J | 1 |
| Cardoit, L | 1 |
| Benazzouz, A | 1 |
| Rui, G | 1 |
| Guangjian, Z | 1 |
| Yong, W | 1 |
| Jie, F | 1 |
| Yanchao, C | 1 |
| Xi, J | 1 |
| Fen, L | 1 |
| Gittis, A | 1 |
| Linazasoro, G | 1 |
| Rafuse, VF | 1 |
| Soundararajan, P | 1 |
| Leopold, C | 1 |
| Robertson, HA | 1 |
| Centonze, D | 1 |
| Gubellini, P | 1 |
| Rossi, S | 1 |
| Picconi, B | 1 |
| Pisani, A | 1 |
| Bernardi, G | 1 |
| Calabresi, P | 1 |
| Baunez, C | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Matsubara, K | 1 |
| Shimizu, K | 1 |
| Suno, M | 1 |
| Ogawa, K | 1 |
| Awaya, T | 1 |
| Yamada, T | 1 |
| Noda, T | 1 |
| Satomi, M | 1 |
| Ohtaki, K | 1 |
| Chiba, K | 1 |
| Tasaki, Y | 1 |
| Shiono, H | 1 |
| Lindgren, HS | 1 |
| Rylander, D | 1 |
| Ohlin, KE | 1 |
| Lundblad, M | 1 |
| Cenci, MA | 1 |
| Olsson, M | 1 |
| Bentlage, C | 1 |
| Björklund, A | 2 |
| Byrnes, EM | 1 |
| Johnson, BJ | 1 |
| Bruno, JP | 1 |
| Matsuura, K | 1 |
| Kabuto, H | 1 |
| Makino, H | 1 |
| Ogawa, N | 1 |
| Johnson, RE | 1 |
| Becker, JB | 1 |
| Campbell, BM | 1 |
| Gresch, PJ | 1 |
| Walker, PD | 1 |
| Crocker, SJ | 1 |
| Wigle, N | 1 |
| Liston, P | 1 |
| Thompson, CS | 1 |
| Lee, CJ | 1 |
| Xu, D | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Park, DS | 1 |
| MacKenzie, A | 1 |
| Korneluk, RG | 1 |
| Robertson, GS | 1 |
| Apicella, P | 2 |
| Trouche, E | 2 |
| Nieoullon, A | 2 |
| Legallet, E | 2 |
| Dusticier, N | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Jenner, PJ | 1 |
| Marsden, CD | 2 |
| Naylor, RJ | 1 |
| Cooper, DR | 1 |
| Marrel, C | 1 |
| van de Waterbeemd, H | 1 |
| Testa, B | 1 |
| Jenner, P | 1 |
| Nishino, H | 2 |
| Ono, T | 2 |
| Takahashi, J | 2 |
| Kimura, M | 2 |
| Shiosaka, S | 2 |
| Yamasaki, H | 1 |
| Hatanaka, H | 1 |
| Tohyama, M | 2 |
| Brundin, P | 1 |
| Isacson, O | 1 |
| Gage, FH | 1 |
| Prochiantz, A | 1 |
| Mintz, M | 1 |
| Douglas, RJ | 1 |
| Tomer, R | 1 |
| de Villiers, AS | 1 |
| Kellaway, L | 1 |
2 reviews available for oxidopamine and Movement Disorders
| Article | Year |
|---|---|
Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Disease Models, Animal; Feeding Behavior; Mice; M | 2012 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
41 other studies available for oxidopamine and Movement Disorders
| Article | Year |
|---|---|
Xanthotoxin reverses Parkinson's disease-like symptoms in zebrafish larvae and mice models: a comparative study.
Topics: Animals; Antiparkinson Agents; Biological Assay; Drug Discovery; Fruit; Larva; Male; Methoxsalen; Mi | 2021 |
The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Choline O-Acetyltransferase; Cognition Disorders; Corpus St | 2014 |
Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Area Under Curve; Disease Models, Animal; Dopamine | 2014 |
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Di | 2015 |
Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system.
Topics: Animals; Brain; Depressive Disorder; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Tran | 2015 |
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamin | 2015 |
Can physical exercise have a protective effect in an animal model of sleep-related movement disorder?
Topics: Animals; Brain; Disease Models, Animal; Electrocorticography; Electromyography; Exercise Therapy; Ex | 2016 |
RNAi-mediated silencing of HLA A2 suppressed acute rejection against human fibroblast xenografts in the striatum of 6-OHDA lesioned rats.
Topics: Adrenergic Agents; Animals; Antigens, CD; Brain Injuries; Corpus Striatum; Disease Models, Animal; F | 2016 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Preventive effects of genistein on motor dysfunction following 6-hydroxydopamine injection in ovariectomized rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Explor | 2008 |
A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats.
Topics: Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Diketopiperazines; | 2009 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Dr | 2009 |
Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Cell Communication; Cell Differentiation; Denervation; Diseas | 2009 |
Deep brain stimulation of the posterior hypothalamic nucleus reverses akinesia in bilaterally 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Avoidance Learning; Catheterization; Deep Brain Stimulation; Electrod | 2009 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
High-frequency stimulation of the subthalamic nucleus restores neural and behavioral functions during reaction time task in a rat model of Parkinson's disease.
Topics: Animals; Cognition Disorders; Deep Brain Stimulation; Disease Models, Animal; Electric Stimulation T | 2010 |
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Dyskinesia, Drug-In | 2010 |
High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats.
Topics: Animals; Deep Brain Stimulation; Electrodes, Implanted; Male; Movement Disorders; Neocortex; Neuroto | 2011 |
Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antioxidants; Disease Models, Animal; Electroencephalography; Gallic Aci | 2011 |
Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing.
Topics: Action Potentials; Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic Neurons; Anim | 2012 |
High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.
Topics: Acupuncture Points; Acupuncture Therapy; Analysis of Variance; Animals; Apomorphine; Biophysical Phe | 2013 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Int | 2012 |
Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog.
Topics: Animals; Antimetabolites; Blotting, Western; Bromodeoxyuridine; Cell Count; Cell Survival; Cells, Cu | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain Injuries; Dopamine | 2006 |
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Resp | 2007 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 1995 |
D1- and D2-receptor mediation of motoric behavior in rats depleted of DA as neonates: effects of age and size of depletion.
Topics: Aging; Animals; Animals, Newborn; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; | 1994 |
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.
Topics: Animals; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred ICR; Movement Disorders; Oxidopa | 1997 |
Akinesia and postural abnormality after unilateral dopamine depletion.
Topics: Animals; Behavior, Animal; Diagnostic Techniques, Neurological; Disease Models, Animal; Dopamine; Fe | 1999 |
Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animals, Newborn; Dopamine; Dopamine Agonists; Dopam | 2001 |
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Amyloid beta-Protein Precursor; Animals; Antibodies; Caspase 3; Caspases; Cell Survival | 2001 |
Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Choline O-Acetyltransferase; Corpus Striatum; Dopami | 1990 |
The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1986 |
Differential time-course of reaction time recovery depending on variations in the amplitude of a goal-directed movement after nigrostriatal lesion in monkeys.
Topics: Animals; Brain Diseases; Caudate Nucleus; Corpus Striatum; Dopamine; Hydroxydopamines; Motor Activit | 1986 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; M | 1987 |
The formation of new neuronal circuit between transplanted nigral dopamine neurons and non-immunoreactive axon terminals in the host rat caudate nucleus.
Topics: Animals; Brain Diseases; Dopamine; Female; Graft Survival; Hydroxydopamines; Microscopy, Electron; M | 1986 |
Transplants in the peri- and intraventricular region grow better than those in the central parenchyma of the caudate.
Topics: Animals; Brain Diseases; Corpus Striatum; Dopamine; Hydroxydopamines; Mesencephalon; Methamphetamine | 1986 |
The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting.
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Corpus Striatum; Disease Models, Animal; Dopamine; Hyd | 1986 |
Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.
Topics: Amphetamine; Animals; Corpus Striatum; Desipramine; Dominance, Cerebral; Drug Tolerance; Hydroxydopa | 1986 |